Endothelial cells internalize and degrade RGD-modified proteins developed for tumor vasculature targeting

Journal of Controlled Release

Volumn 83, Issue 2, 2002, Pages 241-251

  Schraa, Astrid J ^a   Kok, Robbert J ^b   Berendsen, Agnes D ^a   Moorlag, Henk E ^a   Bos, Erwin J ^b   Meijer, Dirk K F ^b   De Leij, Lou F M H ^a   Molema, Grietje ^a,b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

v 3; Intracellular delivery; Macromolecular drug carrier; RGD peptide; Tumor vasculature targeting

Indexed keywords

ARGINYLGLYCYLASPARTIC ACID; BETA3 INTEGRIN; DRUG CARRIER; HUMAN MONOCLONAL ANTIBODY; LIGAND; PROTEIN SUBUNIT; VITRONECTIN;

ARTICLE; BINDING AFFINITY; CELL ADHESION; CONJUGATE; CONTROLLED STUDY; DRUG BINDING; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG TRANSPORT; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; LIGAND BINDING; MACROMOLECULE; PRIORITY JOURNAL; TUMOR VASCULARIZATION; UMBILICAL VEIN;

CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; OLIGOPEPTIDES;

EID: 0037020507     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(02)00206-7     Document Type: Article

References (32)

1. Griffioen A.W., Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 52:2000;237-268.
2. Schraa A.J., Everts M., Kok R.J., Ásgeirsdóttir S.A., Meijer D.K.F., de Leij L.F.M.H., Molema G. El-Gewely M.R., Biotechnology Annual Review. Vol. 8:2002;133-166 Elsevier, Amsterdam.
3. 3 for angiogenesis. Science. 264:1994;569-571.
4. Aplin A.E., Howe A., Alahari S.K., Juliano R.L. Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol. Rev. 50:1998;197-263.
5. 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell. 79:1994;1157-1164.
6. 3 antagonist. J. Clin. Invest. 103:1999;47-54.
7. Arap W., Pasqualini R., Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science. 279:1998;377-380.
8. Ellerby H.M., Arap W., Ellerby L.M., Kain R., Andrusiak R., Rio G.D., Krajewski S., Lombardo C.R., Rao R., Ruoslahti E., Bredesen D.E., Pasqualini R. Anti-cancer activity of targeted pro-apoptotic peptides. Nat. Med. 5:1999;1032-1038.
9. Gerlag D.M., Borges E., Tak P.P., Ellerby H.M., Bredesen D.E., Pasqualini R., Ruoslahti E., Firestein G.S. Suppression of murine collagen-induced arthritis by targeted apoptosis of synovial neovasculature. Arthritis Res. 3:2001;357-361.
10. 3 integrin directed therapeutics. Bioconjug. Chem. 13:2002;128-135.
11. Meijer D.K.F., Ziegler K. Audus K.L., Raub T.J., Biological Barriers to Protein Delivery. 1993;339-408 Plenum, New York.
12. Curnis F., Sacchi A., Borgna L., Magni F., Gasparri A., Corti A. Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 18:2000;1185-1190.
13. Mulder A.B., Blom N.R., Smit J.W., Ruiters M.H., van der M.J., Halie M.R., Bom V.J. Basal tissue factor expression in endothelial cell cultures is caused by contaminating smooth muscle cells. Reduction by using chymotrypsin instead of collagenase. Thromb. Res. 80:1995;399-411.
14. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
15. 3 in the disruption of the tumor vasculature induced by TNF and IFN. Nat. Med. 4:1998;408-414.
16. Hunter W.M., Greenwood F.C. Preparation of iodine-131 labelled growth hormone of high specific activity. Nature. 194:1962;495-496.
17. 3 by low antagonist concentrations. J. Cell Sci. 114:2001;1545-1553.
18. Wild R., Dhanabal M., Olson T.A., Ramakrishnan S. Inhibition of angiogenesis and tumour growth by VEGF121-toxin conjugate: differential effect on proliferating endothelial cells. Br. J. Cancer. 83:2000;1077-1083.
19. Huang X., Molema G., King S., Watkins L., Edgington T.S., Thorpe P.E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science. 275:1997;547-550.
20. 1 integrins. J. Biol. Chem. 269:1994;20233-20238.
21. Koivunen E., Wang B., Ruoslahti E. Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Bio/Technology. 13:1995;265-270.
22. v integrins in adenovirus cell entry and gene delivery. Microbiol. Mol. Biol. Rev. 63:1999;725-734.
23. Savill J., Dransfield I., Hogg N., Haslett C. Vitronectin receptor-mediated phagocytosis of cells undergoing apoptosis. Nature. 343:1990;170-173.
24. 3. J. Biol. Chem. 272:1997;2736-2743.
25. 5 integrin functions as an endocytic receptor for vitronectin. J. Cell Sci. 111:1998;425-433.
26. Buckley C.D., Pilling D., Henriquez N.V., Parsonage G., Threlfall K., Scheel-Toellner D., Simmons D.L., Akbar A.N., Lord J.M., Salmon M. RGD peptides induce apoptosis by direct caspase-3 activation. Nature. 397:1999;534-539.
27. v-integrin, enter the cells by independent endocytic pathways. Lab. Invest. 81:2001;1615-1626.
28. Yamada K.M., Miyamoto S. Integrin transmembrane signaling and cytoskeletal control. Curr. Opin. Cell Biol. 7:1995;681-689.
29. Lamaze C., Fujimoto L.M., Yin H.L., Schmid S.L. The actin cytoskeleton is required for receptor-mediated endocytosis in mammalian cells. J. Biol. Chem. 272:1997;20332-20335.
30. Kok R.J., Ásgeirsdóttir S.A., Verweij W.R. Molema G., Meijer D.K.F., Drug Targeting: Organ-Specific Strategies. 2001;275-308 Wiley-VCH, Weinheim.
31. v integrins during angiogenesis: insights into potential mechanisms of action and clinical development. J. Clin. Invest. 103:1999;1227-1230.
32. 3. Clin. Cancer Res. 6:2000;3056-3061.